Systemic sclerosis and the gut

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 4, 2013, Pages 331-339

  Butt, Shamaila ^a   Emmanuel, Anton ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

bacterial overgrowth; biofeedback; constipation dysphagia; fecal incontinence; GAVE; hemorrhage; interstitial lung disease; neuropathy; PTNS; reflux; scleroderma; SNS; systemic sclerosis

Indexed keywords

ALVIMOPAN; CISAPRIDE; DOMPERIDONE; ERYTHROMYCIN; IRON; LAXATIVE; LOPERAMIDE; METOCLOPRAMIDE; OCTREOTIDE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; PRUCALOPRIDE; TEGASEROD;

BLOATING; BLOOD TRANSFUSION; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DRUG MECHANISM; DYSPHAGIA; ESOPHAGUS DISEASE; ESOPHAGUS RESECTION; EXTRAPYRAMIDAL SYMPTOM; FECES INCONTINENCE; GASTRIC DYSMOTILITY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HEARTBURN; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG TRANSPLANTATION; MALNUTRITION; MORBIDITY; MORTALITY; PELVIC FLOOR MUSCLE TRAINING; REVIEW; ROUX Y ANASTOMOSIS; SATIETY; SYSTEMIC SCLEROSIS; WEIGHT REDUCTION;

GASTROINTESTINAL DISEASES; HUMANS; PROGNOSIS; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 84877286628     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.13.22     Document Type: Review

References (54)

1. LeRoy EC, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 28
2. Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment. Pharmacol. Ther. 23(6), 691-712 (2006).
3. Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology 48(Suppl. 3), 36 (2009).
4. Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut 55(12), 1697-1703 (2006).
5. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 43(11), 2437-2444 (2000).
6. Omair MA, Lee P. Effect of gastrointestinal manifestations on quality of life in consecutive patients with systemic sclerosis. J. Rheumatol. 39(5), 992-996 (2012).
7. Khanna D, Furst DE, Maranian P et al. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. J. Rheumatol. 38(9), 1920-1924 (2011).
8. Basilisco G, Carola F, Vanoli M, Bianchi P, Barbera R. Oesophageal acid clearance in patients with systemic sclerosis: effect of body position. Eur. J. Gastroenterol. Hepatol. 8(3), 205-209 (1996).
9. Mercado U, Arroyo de Anda R, Avendaño L, Araiza-Casillas R, Avendaño-Reyes M. Metoclopramide response in patients with early diffuse systemic sclerosis. Effects on esophageal motility abnormalities. Clin. Exp. Rheumatol. 23(5), 685-688 (2005).
10. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am. J. Med. 118(1), 2-10 (2005).
11. Cantu E 3rd, Appel JZ 3rd, Hartwig MG et al. J. Maxwell Chamberlain memorial paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann. Thorac. Surg. 78(4), 1142-1151; discussion
12. Christmann RB, Wells AU, Capelozzi VL, Silver RM. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin. Arthritis Rheum. 40(3), 241-249 (2010)
13. Poirier NC, Taillefer R, Topart P, Duranceau A. Antireflux operations in patients with scleroderma. Ann. Thorac. Surg. 58(1), 66-72; discussion 72 (1994).
14. Kent MS, Luketich JD, Irshad K et al. Comparison of surgical approaches to recalcitrant gastroesophageal reflux disease in the patient with scleroderma. Ann. Thorac. Surg. 84(5), 1710-1715; discussion
15. Conio M, Blanchi S, Lapertosa G et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am. J. Gastroenterol. 98(9), 1931-1939 (2003).
16. Wipff J, Coriat R, Masciocchi M et al. Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study. Rheumatology 50
17. Wang KK, Sampliner RE; Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am. J. Gastroenterol. 103(3), 788-797 (2008).
18. Ebert EC. Esophageal disease in scleroderma. J. Clin. Gastroenterol. 40(9), 769-775 (2006).
19. Zamost BJ, Hirschberg J, Ippoliti AF, Furst DE, Clements PJ, Weinstein WM. Esophagitis in scleroderma. Prevalence and risk factors. Gastroenterology 92(2), 421-428 (1987).
20. Ibba-Manneschi L, Del Rosso A, Pacini S, Tani A, Bechi P, Matucci Cerinic M. Ultrastructural study of the muscle coat of the gastric wall in a case of systemic sclerosis. Ann. Rheum. Dis. 61(8), 754-756 (2002).
21. Ebert EC. Gastric and enteric involvement in progressive systemic sclerosis. J. Clin. Gastroenterol. 42(1), 5-12 (2008).
22. Marie I, Levesque H, Ducrotté P et al. Gastric involvement in systemic sclerosis: a prospective study. Am. J. Gastroenterol. 96(1), 77-83 (2001).
23. Marie I, Levesque H, Ducrotté P et al. Manometry of the upper intestinal tract in patients with systemic sclerosis: a prospective study. Arthritis Rheum. 41(10), 1874-1883 (1998).
24. Franck-Larsson K, Hedenström H, Dahl R, Rönnblom A. Delayed gastric emptying in patients with diffuse versus limited systemic sclerosis, unrelated to gastrointestinal symptoms and myoelectric gastric activity. Scand. J. Rheumatol. 32(6), 348-355 (2003).
25. Sridhar KR, Lange RC, Magyar L, Soykan I, McCallum RW. Prevalence of impaired gastric emptying of solids in systemic sclerosis: diagnostic and therapeutic implications. J. Lab. Clin. Med. 132(6), 541-546 (1998).
26. Johnson DA, Drane WE, Curran J et al. Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities. Arch. Intern. Med. 147(9), 1597-1601 (1987).
27. Fiorucci S, Distrutti E, Bassotti G et al. Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients. Scand. J. Gastroenterol. 29(9), 807-813 (1994).
28. Fiorucci S, Distrutti E, Gerli R, Morelli A. Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term. Am. J. Gastroenterol. 89(4), 550-555 (1994).
29. Linke R, Meier M, Muenzing W, Folwaczny C, Schnell O, Tatsch K. Prokinetic therapy: what can be measured by gastric scintigraphy? Nucl. Med. Commun. 26(6), 527-533 (2005).
30. Marie I, Ducrotte P, Antonietti M, Herve S, Levesque H. Watermelon stomach in systemic sclerosis: its incidence and management. Aliment. Pharmacol. Ther. 28(4), 412-421 (2008).
31. Ingraham KM, O'Brien MS, Shenin M, Derk CT, Steen VD. Gastric antral vascular ectasia in systemic sclerosis: demographics and disease predictors. J. Rheumatol. 37(3), 603-607 (2010).
32. Johnson J, Derk CT. Gastric antral vascular ectasia in systemic sclerosis. Int. J. Rheumatol. 2011, 305238 (2011).
33. Yusoff I, Brennan F, Ormonde D, Laurence B. Argon plasma coagulation for treatment of watermelon stomach. Endoscopy 34(5), 407-410 (2002).
34. Schulz SW, O'Brien M, Maqsood M, Sandorfi N, Del Galdo F, Jimenez SA. Improvement of severe systemic sclerosisassociated gastric antral vascular ectasia following immunosuppressive treatment with intravenous cyclophosphamide. J. Rheumatol. 36(8), 1653-1656 (2009).
35. Catanoso M, Lo Gullo R, Giofré MR et al. Gastro-intestinal permeability is increased in patients with limited systemic sclerosis. Scand. J. Rheumatol. 30(2), 77-81 (2001).
36. Pickhardt PJ. The 'hide-bound' bowel sign. Radiology 213(3), 837-838 (1999).
37. Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin. Investig. Drugs 18(3), 349-358 (2009).
38. Scarpellini E, Gabrielli M, Lauritano CE et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment. Pharmacol. Ther. 25(7), 781-786 (2007).
39. Nikou GC, Toumpanakis C, Katsiari C, Charalambopoulos D, Sfikakis PP. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J. Clin. Rheumatol. 13(3), 119-123 (2007).
40. Verne GN, Eaker EY, Hardy E, Sninsky CA. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudo-obstruction. Dig. Dis. Sci. 40(9), 1892-1901 (1995).
41. Gyger G, Baron M. Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr. Rheumatol. Rep. 14, 22 (2012).
42. Lal S, Teubner A, Shaffer JL. Review article: intestinal failure. Aliment. Pharmacol. Ther. 24(1), 19-31 (2006).
43. Emmanuel AV, Tack J, Quigley EM, Talley NJ. Pharmacological management of constipation. Neurogastroenterol. Motil. 21(Suppl. 2), 41-54 (2009).
44. Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal manifestations of systemic sclerosis. Dig. Dis. Sci. 53(5), 1163-1174 (2008).
45. Tack J, Müller-Lissner S, Stanghellini V et al. Diagnosis and treatment of chronic constipation - a European perspective. Neurogastroenterol. Motil. 23(8), 697-710 (2011).
46. Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am. J. Gastroenterol. 97(1), 194-197 (2002).
47. Kamm MA, Dudding TC, Melenhorst J et al. Sacral nerve stimulation for intractable constipation. Gut 59(3), 333-340 (2010).
48. Thoua NM, Bunce C, Brough G, Forbes A, Emmanuel AV, Denton CP. Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. Rheumatology (Oxf.) 49(9), 1770-1775 (2010).
49. Thoua NM, Abdel-Halim M, Forbes A, Denton CP, Emmanuel AV. Fecal incontinence in systemic sclerosis is secondary to neuropathy. Am. J. Gastroenterol. 107(4), 597-603 (2012).
50. Thoua NM, Schizas A, Forbes A, Denton CP, Emmanuel AV. Internal anal sphincter atrophy in patients with systemic sclerosis. Rheumatology (Oxford) 50(9), 1596-1602 (2011).
51. Kenefick NJ, Vaizey CJ, Nicholls RJ, Cohen R, Kamm MA. Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut 51(6), 881-883 (2002).
52. Glasgow SC, Lowry AC. Long-term outcomes of anal sphincter repair for fecal incontinence: a systematic review. Dis. Colon Rectum 55(4), 482-490 (2012).
53. Chatterjee S. Watermelon stomach. CMAJ 179(2), 162 (2008).
54. Scleroderma bowel. www.learningradiology.com